Scholarlink

<p>The impact of progesterone receptor (PR) expression level on breast cancer prognosis in relation to menopausal status is unclear. This study evaluated the impact of the association between PR expression level and menopausal status on prognosis in patients with estrogen receptor (ER)-positive (&gt; 10%)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We retrospectively identified 2,796 patients with ER-positive/HER2-negative early breast cancer and classified them into three groups based on PR expression levels: PR-high (&gt; 10%), PR-low (1–10%), and PR-zero (&lt; 1%). We compared the cumulative incidence of any recurrence (AR) and distant recurrence (DR) among the three groups by menopausal status. Over a median follow-up of 84.5 months, there were 324 AR and 264 DR events. In premenopausal patients, the PR-zero group (1,155 patients) had a significantly worse prognosis than did the PR-low (44 patients) and PR-high (60 patients) groups. Meanwhile, postmenopausal patients in the PR-zero (219 patients) and PR-low (167 patients) groups had similar prognosis, both significantly worse than the PR-high group (1,151 patients). Varying cutoff values of PR expression according to menopausal status could help determine more personalized treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of progesterone receptors with different cutoff values according to menopausal status in hormone-positive early breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月14日

查看全文
  • Ayumi Ogawa,
  • Takeshi Murata,
  • Masayuki Yoshida,
  • Natsuko Ohgi,
  • Hiromi Hashiguchi,
  • Ayako Nakashoji,
  • Hinako Maeda,
  • Chikashi Watase,
  • Eriko Iwamoto,
  • Shin Takayama

摘要

The impact of progesterone receptor (PR) expression level on breast cancer prognosis in relation to menopausal status is unclear. This study evaluated the impact of the association between PR expression level and menopausal status on prognosis in patients with estrogen receptor (ER)-positive (> 10%)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We retrospectively identified 2,796 patients with ER-positive/HER2-negative early breast cancer and classified them into three groups based on PR expression levels: PR-high (> 10%), PR-low (1–10%), and PR-zero (< 1%). We compared the cumulative incidence of any recurrence (AR) and distant recurrence (DR) among the three groups by menopausal status. Over a median follow-up of 84.5 months, there were 324 AR and 264 DR events. In premenopausal patients, the PR-zero group (1,155 patients) had a significantly worse prognosis than did the PR-low (44 patients) and PR-high (60 patients) groups. Meanwhile, postmenopausal patients in the PR-zero (219 patients) and PR-low (167 patients) groups had similar prognosis, both significantly worse than the PR-high group (1,151 patients). Varying cutoff values of PR expression according to menopausal status could help determine more personalized treatment strategies.